{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06285097",
            "orgStudyIdInfo": {
                "id": "C5391001"
            },
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
            "officialTitle": "A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-pf-as-a-single-agent-and-in-combination-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-04-29",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-23",
            "studyFirstSubmitQcDate": "2024-02-26",
            "studyFirstPostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasms",
                "Non-small-cell Lung Cancer",
                "Melanoma",
                "Squamous Cell Carcinoma of the Head and Neck",
                "Renal Cell Carcinoma",
                "Urothelial Carcinoma",
                "Colorectal Carcinoma",
                "Ovarian Carcinoma"
            ],
            "keywords": [
                "Sasanlimab",
                "anti-Programmed death receptor-1 (PD-1)",
                "solid tumor",
                "immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy dose escalation (Part 1A)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles",
                    "interventionNames": [
                        "Drug: PF-07820435"
                    ]
                },
                {
                    "label": "Combination dose escalation (Part 1B)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07820435 orally at the prescribed dose and frequency, in combination with sasanlimab (subcutaneous injection) at a fixed dose once every 4 weeks in 28-day cycles",
                    "interventionNames": [
                        "Drug: PF-07820435",
                        "Biological: Sasanlimab"
                    ]
                },
                {
                    "label": "Expansion (Part 2) - Tumor specific Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles",
                    "interventionNames": [
                        "Drug: PF-07820435",
                        "Biological: Sasanlimab"
                    ]
                },
                {
                    "label": "Expansion (Part 2) - Tumor specific Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles",
                    "interventionNames": [
                        "Drug: PF-07820435",
                        "Biological: Sasanlimab"
                    ]
                },
                {
                    "label": "Expansion (Part 2) - Arm C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles",
                    "interventionNames": [
                        "Drug: PF-07820435"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PF-07820435",
                    "description": "immune agonist",
                    "armGroupLabels": [
                        "Combination dose escalation (Part 1B)",
                        "Expansion (Part 2) - Arm C",
                        "Expansion (Part 2) - Tumor specific Arm A",
                        "Expansion (Part 2) - Tumor specific Arm B",
                        "Monotherapy dose escalation (Part 1A)"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Sasanlimab",
                    "description": "A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2",
                    "armGroupLabels": [
                        "Combination dose escalation (Part 1B)",
                        "Expansion (Part 2) - Tumor specific Arm A",
                        "Expansion (Part 2) - Tumor specific Arm B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B)",
                    "description": "DLT rate estimated based on data from DLT-evaluable participants during the DLT evaluation period",
                    "timeFrame": "Baseline through 28 days after first dose"
                },
                {
                    "measure": "Number of patients with adverse events (AEs)",
                    "description": "Characterized by type, frequency, severity (CTCAE v5; CRS by ASTCT), timing, seriousness, and relationship to study drug(s)",
                    "timeFrame": "Baseline through up to 2 years"
                },
                {
                    "measure": "Number of patients with clinically significant lab abnormalities",
                    "description": "Characterized by type, frequency, severity (CTCAE v5), and timing",
                    "timeFrame": "Baseline through up to 2 years"
                },
                {
                    "measure": "Objective response rate (ORR) in Part 2 Expansion",
                    "description": "Tumor response as assessed using RECIST 1.1",
                    "timeFrame": "Baseline through 2 years or disease progression"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR) in dose escalation (Part 1A and Part 1B)",
                    "description": "Tumor response as assessed by RECIST 1.1",
                    "timeFrame": "Baseline through 2 years or disease progression"
                },
                {
                    "measure": "Duration of tumor response",
                    "description": "Tumor response as assessed by RECIST 1.1",
                    "timeFrame": "Baseline through 2 years or disease progression"
                },
                {
                    "measure": "Progression free survival (PFS)",
                    "description": "Tumor response as assessed by RECIST 1.1",
                    "timeFrame": "Baseline through 2 years or disease progression"
                },
                {
                    "measure": "Cmax (maximum concentration) of PF-07820435 and its active metabolite",
                    "description": "Single and multiple dose PK parameters of PF-07820435 and its active metabolite",
                    "timeFrame": "Serial timepoints following the first dose (Day 1), second dose (Day 8), and third dose (Day 15) of the first cycle (each cycle is 28 days); and Day 1 (dosing) of Cycle 2 and Day 1 (dosing) of Cycle 3."
                },
                {
                    "measure": "Tmax (time to maximal plasma concentration) of PF-07820435 and its active metabolite",
                    "description": "Single and multiple dose PK parameters of PF-07820435 and its active metabolite",
                    "timeFrame": "Serial timepoints following the first dose (Day 1), second dose (Day 8), and third dose (Day 15) of the first cycle (each cycle is 28 days); and Day 1 (dosing) of Cycle 2 and Day 1 (dosing) of Cycle 3."
                },
                {
                    "measure": "AUClast (area under the curve from time 0 to the last measurable timepoint) of PF-07820435 and its active metabolite",
                    "description": "Single and multiple dose PK parameters of PF-07820435 and its active metabolite",
                    "timeFrame": "Serial timepoints following the first dose (Day 1), second dose (Day 8), and third dose (Day 15) of the first cycle (each cycle is 28 days); and Day 1 (dosing) of Cycle 2 and Day 1 (dosing) of Cycle 3."
                },
                {
                    "measure": "Cmin (minimum concentration) of PF-07820435 and its active metabolite after multiple dosing only",
                    "description": "Multiple dose PK parameters of PF-07820435 and its active metabolite",
                    "timeFrame": "Serial timepoints following the first dose (Day 1), second dose (Day 8), and third dose (Day 15) of the first cycle (each cycle is 28 days); and Day 1 (dosing) of Cycle 2 and Day 1 (dosing) of Cycle 3."
                },
                {
                    "measure": "Change from baseline of immune markers within biopsied tumor tissue",
                    "description": "Change in CD8 immune marker will be analyzed",
                    "timeFrame": "Baseline through about 6 weeks after first dose"
                },
                {
                    "measure": "Pre-dose trough concentrations of sasanlimab (Part 1B and Part 2)",
                    "description": "Single and multiple dose PK parameters of sasanlimab",
                    "timeFrame": "Day 1 (pre-dose) of each cycle (28 days) for the first 3 cycles, then Day 1 on every 3rd cycle until 2 years or disease progression"
                },
                {
                    "measure": "Incidence and titers of ADA and NAb against sasanlimab (Part 1B and Part 2)",
                    "description": "Immunogenicity assessment",
                    "timeFrame": "Day 1 (pre-dose) of each cycle (28 days) for the first 3 cycles, then Day 1 on every 3rd cycle until 2 years or disease progression"
                },
                {
                    "measure": "Cmax of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2",
                    "description": "The analysis applies to Part 2 Food Effect Subset only",
                    "timeFrame": "On Day 1 (first dose) and Day 15 (third dose): Pre-dose, 0.5 hour (h), 1h, 2h, 4h, 6h, and 24h post dose."
                },
                {
                    "measure": "Tmax of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2",
                    "description": "The analysis applies to Part 2 Food Effect Subset only",
                    "timeFrame": "On Day 1 (first dose) and Day 15 (third dose): Pre-dose, 0.5 hour (h), 1h, 2h, 4h, 6h, and 24h post dose."
                },
                {
                    "measure": "AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2",
                    "description": "The analysis applies to Part 2 Food Effect Subset only",
                    "timeFrame": "On Day 1 (first dose) and Day 15 (third dose): Pre-dose, 0.5 hour (h), 1h, 2h, 4h, 6h, and 24h post dose."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor\n* Part 1A: Participants with solid tumors where anti-PD-(L)1 is an established treatment. Participants must have progressed on or following prior anti-PD-(L)1 therapy if approved, available, tolerable, and eligible\n* Part 1B: Participants either meeting Part 1A criterion, or participants with \"cold\" solid tumors where anti-PD-(L)1 therapy is not an established treatment\n* Part 2: Participants with NSCLC (Arm A) must have received platinum-based chemotherapy and anti-PD-(L)1 or have intolerability to or refusal of standard therapies. NSCLC participants with known activating mutation(s) must also have received prior approved and available targeted therapy(ies) for the associated mutation(s) or have intolerability or documented refusal of these therapies. Participants with UC (Arm B) must have received prior platinum-based chemotherapy, anti-PD-(L)1 therapy, or enfortumab vedotin, or have documented intolerability or refusal of the standard therapy(ies). Additional cohort indication(s) or dose regimens may be added and defined based on emerging data\n* At least 1 measurable lesion based on RECIST 1.1 that has not been previously irradiated (Part 1 exceptions permitted after review and approval)\n* Able to provide pre-treatment (and optional on-treatment) tumor tissue\n\nExclusion Criteria:\n\n* Active or history of clinically significant gastrointestinal disease and other conditions that are unresolved or pose a risk to study treatment or procedures\n* Active or history of pneumonitis/interstitial lung disease, pulmonary fibrosis requiring treatment with systemic steroid therapy\n* Active or history of clinically significant autoimmune disease or other medical condition that required chronic systemic immunosuppressive therapy within recent 2 years\n* History of severe immune-mediated adverse event or cytokine release syndrome that was considered related to prior immune modulatory therapy that required immunosuppressive therapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "AdventHealth Celebration Infusion Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Celebration",
                    "state": "Florida",
                    "zip": "34747",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.32529,
                        "lon": -81.53313
                    }
                },
                {
                    "facility": "AdventHealth Celebration",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Celebration",
                    "state": "Florida",
                    "zip": "34747",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.32529,
                        "lon": -81.53313
                    }
                },
                {
                    "facility": "Florida Cancer Specialists Sarasota Drug Development Unit",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Corewell Health (reference non-engagement letter)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49503",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "START Midwest",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Hackensack University Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "John Theurer Cancer Center at Hackensack University Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute - Pharmacy",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Tristar Centennial Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Kashiwa",
                    "state": "Chiba",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "The Cancer Institute Hospital of JFCR",
                    "status": "RECRUITING",
                    "city": "Koto",
                    "state": "Tokyo",
                    "zip": "135-8550",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.66667,
                        "lon": 139.81718
                    }
                },
                {
                    "facility": "Hospital Oncologico Dr. Isaac Gonzalez-Martinez",
                    "status": "RECRUITING",
                    "city": "Rio Piedras",
                    "zip": "00935",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39745,
                        "lon": -66.04989
                    }
                },
                {
                    "facility": "Pan American Center for Oncology Trials, LLC",
                    "status": "RECRUITING",
                    "city": "Rio Piedras",
                    "zip": "00935",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39745,
                        "lon": -66.04989
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=C5391001"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002292",
                    "term": "Carcinoma, Renal Cell"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                },
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000007680",
                    "term": "Kidney Neoplasms"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Squamous Cell Carcinoma of the Head and Neck",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M6845",
                    "name": "Death",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "asFound": "Renal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10703",
                    "name": "Kidney Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "asFound": "Renal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1341",
                    "name": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}